Since the March 22, 2024 podcast, there has been clear early progress toward using genetically modified pig organs in humans, but these procedures remain highly experimental and far from routine clinical practice.

Key developments:

• Massachusetts General Hospital performed the first transplant of a genetically edited pig kidney into a living human in March 2024 and a second such transplant in January 2025; by early 2025, this was only the fourth pig-kidney recipient worldwide, underscoring how rare the procedure still is. (hms.harvard.edu)
• In February 2025, the U.S. FDA approved the first formal clinical trials of gene‑edited pig kidneys for patients with end‑stage kidney disease, with plans for up to ~50 participants across studies by United Therapeutics and eGenesis. (scientificamerican.com)
• By November 2025, NYU Langone had only just begun enrolling and operating on patients in one of these kidney xenotransplant trials. (news-medical.net)
• Additional experimental uses—such as FDA‑approved trials of gene‑edited pig livers used externally as a dialysis‑like bridge for liver failure, and pig lung transplants into brain‑dead donors for research—also remain investigational rather than standard care. (apnews.com)

These steps support the possibility that genetically modified animal organs could become a mainstream solution in the longer term, but they do not yet demonstrate that such organs are on a clearly established path to routine clinical use. Given that (1) only a handful of patients worldwide have received such organs in living clinical settings, (2) trials are just beginning, and (3) large‑scale safety, efficacy, regulatory approval, reimbursement, and ethical questions remain unresolved, it is too early in November 2025 to say whether the prediction that this will "definitely" become a widely adopted, mainstream medical solution is ultimately right or wrong.

Therefore, the appropriate judgment at this time is inconclusive (too early to tell).